Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and
Received FDA Agreement Under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical TrialPositive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing Phase 2 Clinical Trial with Suprachoroidal Administration Presented at AAO 2023Preliminary Data from Phase 1 Trial in...
United States Los Pinos J Jill Hopkins Mark Plavsic Technology Officer Suprachoroidal Administration
Source: pharmiweb.com